-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, RHo449Lak3RRuaeTs31WGaCflsCdQZ/1K/y+YUzYT+ji2QDFNs035IilwqcvPM/+ DcvLxEmzGP9JSgH2efzXhg== 0000929638-01-500170.txt : 20010815 0000929638-01-500170.hdr.sgml : 20010815 ACCESSION NUMBER: 0000929638-01-500170 CONFORMED SUBMISSION TYPE: SC 13D/A PUBLIC DOCUMENT COUNT: 3 FILED AS OF DATE: 20010814 GROUP MEMBERS: AIM HIGH ENTERPRISES, INC. GROUP MEMBERS: KAIROS PARTNERS GP, LLC GROUP MEMBERS: KAIROS PARTNERS, LP GROUP MEMBERS: STONEGATE PARTNERS, LLC SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: IMMUCOR INC CENTRAL INDEX KEY: 0000736822 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 222408354 STATE OF INCORPORATION: GA FISCAL YEAR END: 0531 FILING VALUES: FORM TYPE: SC 13D/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-37473 FILM NUMBER: 1708703 BUSINESS ADDRESS: STREET 1: 3130 GATWAY STREET 2: PO BOX 5625 CITY: NORCROSS STATE: GA ZIP: 30091 BUSINESS PHONE: 7704412051 MAIL ADDRESS: STREET 1: 3130 GATEWAY DR STREET 2: P O BOX 5625 CITY: NORCROSS STATE: GA ZIP: 30091-5625 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: KAIROS PARTNERS LP CENTRAL INDEX KEY: 0001122689 STANDARD INDUSTRIAL CLASSIFICATION: [] FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D/A BUSINESS ADDRESS: STREET 1: 600 LONGWATER DRIVE STREET 2: SUITE 204 CITY: NORWELL STATE: MA ZIP: 02061 BUSINESS PHONE: 7816351100X1123 MAIL ADDRESS: STREET 1: 600 LONGWATER DR. STREET 2: SUITE 204 CITY: NORWELL STATE: MA ZIP: 02061 SC 13D/A 1 a1026637.txt AMENDMENT NO. 6 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D (RULE 13D-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13D-1(A) AND AMENDMENTS THERETO FILED PURSUANT TO 13D-2(A) (AMENDMENT NO. 6)* Immucor, Inc. - ------------------------------------------------------------------------------- (Name of Issuer) Common Stock, $.10 par value - ------------------------------------------------------------------------------- (Title of Class of Securities) 452526106 - ------------------------------------------------------------------------------- (CUSIP Number) James F. Rice, Managing Director c/o Aim High Enterprises, Inc. 600 Longwater Drive, Suite 204 Norwell, MA 02061 (781) 635-1121 - ------------------------------------------------------------------------------- (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) August 9, 2001 - ------------------------------------------------------------------------------- (Date of Event which Requires Filing of this Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(b)(3) or (4), check the following box [ ]. NOTE: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7(b) for other parties to whom copies are to be sent. (Continued on the following pages) (Page 1 of 11 Pages) - ---------------- * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. 452526106 13D/A PAGE 2 OF 8 - ------------------------------------------------------------------------------- 1 NAMES OF REPORTING PERSONS S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY) Kairos Partners, LP (Tax ID: 04-3521249) Kairos Partners GP, LLC Aim High Enterprises, Inc. StoneGate Partners, LLC - ------------------------------------------------------------------------------- 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (A) [ ] (B) x - ------------------------------------------------------------------------------- 3 SEC USE ONLY - ------------------------------------------------------------------------------- 4 SOURCE OF FUNDS (SEE INSTRUCTIONS) WC--SEE ITEM 3 - ------------------------------------------------------------------------------- 5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(D) OR 2(E) [ ] - ------------------------------------------------------------------------------- 6 CITIZENSHIP OR PLACE OF ORGANIZATION Kairos Partners, LP is a Delaware limited partnership. Kairos Partners GP, LLC is a Delaware limited liability corporation. Aim High Enterprises, Inc. is a Delaware corporation. StoneGate Partners, LLC is a Massachusetts limited liability corporation. - ------------------------------------------------------------------------------- 7 SOLE VOTING POWER None ---------------------------------------------------------------- NUMBER OF 8 SHARED VOTING POWER SHARES BENEFICIALLY 728,170 shares--See Item 5 OWNED BY ---------------------------------------------------------------- EACH 9 SOLE DISPOSITIVE POWER REPORTING PERSON WITH None ---------------------------------------------------------------- 10 SHARED DISPOSITIVE POWER 728,170 shares--See Item 5 - ------------------------------------------------------------------------------- 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 728,170 shares--See Item 5 - ------------------------------------------------------------------------------- 12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) [ ] Not Applicable. CUSIP No. 452526106 13D/A PAGE 3 OF 8 - ------------------------------------------------------------------------------- 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 10.0% (based on 7,277,617 shares of Common Stock outstanding as of April 12, 2001, as reported by the Issuer in its Form 10-Q for the quarter ended February 28, 2001). - ------------------------------------------------------------------------------- 14 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) Kairos Partners, LP--PN Kairos Partners GP, LLC--OO (limited liability company) Aim High Enterprises, Inc.--CO StoneGate Partners, LLC--OO (limited liability company) - ------------------------------------------------------------------------------- ITEM 1. SECURITY AND ISSUER: (a) This Amendment No. 5 relates to the common stock, $.10 par value per share, of Immucor, Inc. (the "Common Stock"). (b) The names and addresses of the principal executive officers of the Issuer are as follows: Edward L. Gallup, President and Chief Executive Officer Ralph A. Eatz, Senior Vice President - Operations Dr. Gioacchhino De Chirico, Director of European Operations and President, Immucor Italia S.r.1 Steven C. Ramsey, Vice President - Chief Financial Officer and Secretary Patrick Waddy, President of Dominion Biologicals Limited and European Finance Director Address: c/o Immucor, Inc. 3130 Gateway Drive P.O. Box 5625 Norcross, Georgia 30091 ITEM 2. IDENTITY AND BACKGROUND 1. (a) Kairos Partners, LP, a limited partnership organized under the laws of the State of Delaware ("Kairos"). (b) Address: c/o Aim High Enterprises, Inc. 600 Longwater Drive, Suite 204 Norwell, MA 02061 (c) Principal Business: Investments (d) During the last five years, Kairos has not been convicted in a criminal proceeding. CUSIP No. 452526106 13D/A PAGE 4 OF 8 (e) During the last five years, Kairos was not a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws 2. (a) Kairos Partners GP, LLC, a limited liability corporation organized under the laws of the State of Delaware ("Kairos GP"). Kairos GP is the general partner of Kairos. (b) Address: c/o Aim High Enterprises, Inc. 600 Longwater Drive, Suite 204 Norwell, MA 02061 (c) Principal Business: Investments (d) During the last five years, Kairos GP has not been convicted in a criminal proceeding. (e) During the last five years, Kairos GP was not a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws 3. (a) Aim High Enterprises, Inc. jointly controls Kairos GP with StoneGate Partners, LLC (see below). (b) Address: Aim High Enterprises, Inc. 600 Longwater Drive, Suite 204 Norwell, MA 02061 (c) Principal Business: Investments (d) During the last five years, Aim High Enterprises, Inc. has not been convicted in a criminal proceeding. (e) During the last five years, Aim High Enterprises, Inc. was not a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws. (f) Aim High Enterprises, Inc. is a corporation organized under the laws of the State of Delaware. CUSIP No. 452526106 13D/A PAGE 5 OF 8 4. (a) StoneGate Partners, LLC jointly controls Kairos GP with Aim High Enterprises, Inc. (see above). (b) Address: StoneGate Partners, LLC 45 Milk Street, 7th Floor Boston, MA 02109 (c) Principal Business: Investments (d) During the last five years, StoneGate Partners, LLC has not been convicted in a criminal proceeding. (e) During the last five years, StoneGate Partners, LLC was not a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws. (f) StoneGate Partners, LLC is a limited liability company organized under the laws of the Commonwealth of Massachusetts. ITEM 3. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION: Not applicable. ITEM 4. PURPOSE OF TRANSACTION: Kairos acquired the shares of Common Stock for investment purposes. Kairos reserves the right from time to time to acquire additional shares, or to dispose of some or all of its shares. (a) Not applicable (b) Not applicable (c) Not applicable. (d) In accordance with the Issuer's By-laws, by notice from Kairos to the Issuer, dated August 9, 2001, a copy of which is attached as Exhibit 99.1, Kairos proposed the nomination of four individuals for election to Issuer's Board of Directors at the next annual meeting of stockholders of the Issuer. By letter from Kairos to the Issuer, dated August 10, 2001, a copy of which is attached as Exhibit 99.2, John F. White, Principal of Kairos, informed the Issuer that Kairos intends to deliver a proxy statement and form of proxy to holders of at least the percentage of holders of CUSIP No. 452526106 13D/A PAGE 6 OF 8 Common Stock required under Georgia law to elect some or all of Kairos' nominees to the Issuer's Board of Directors at the next annual meeting of stockholders of the Issuer. In addition, Mr. White also requested, on behalf of Kairos, a current list of all record and beneficial holders of Common Stock in accordance with the requirements set forth in Rule 14a-7. (e) Not applicable. (f) See Item (d) above. (g) Not applicable. (h) Not applicable. (i) Not applicable. (j) Not applicable. ITEM 5. INTEREST IN SECURITIES OF THE ISSUER: a) The following list sets forth the aggregate number and percentage (based on 7,277,617 shares of Common Stock outstanding as of April 12, 2001 as reported by the Issuer in its Form 10-Q for the quarter ended February 28, 2001) of outstanding shares of Common Stock owned beneficially by each reporting person named in Item 2, as of July 30, 2001: - ------------------------------------------------------------------------------- Name Shares of Common Stock Percentage of Beneficial Beneficially Owned Ownership - ------------------------------------------------------------------------------- - ------------------------------------------------------------------------------- Kairos Partners, LP 728,170 10.0% - ------------------------------------------------------------------------------- Kairos Partners GP, LLC(1) 728,170 10.0% - ------------------------------------------------------------------------------- Aim High Partners, Inc.(1) 728,170 10.0% - ------------------------------------------------------------------------------- StoneGate Partners, LLC(1) 728,170 10.0% - ------------------------------------------------------------------------------- (1) The reporting person disclaims beneficial ownership of these securities except to the extent of his/its equity interest therein. (b) Kairos has sole power to vote and to dispose of 728,170 shares of Common Stock, representing 10.0% of the outstanding Common Stock. Kairos GP, by virtue of being the general partner of Kairos, may be deemed to have shared power to vote and to dispose of 728,170 shares of Common Stock, representing 10.0% of the outstanding Common Stock. CUSIP No. 452526106 13D/A PAGE 7 OF 8 Aim High Enterprises, Inc., by virtue of being a joint controller of Kairos GP with StoneGate Partners, LLC, may be deemed to have shared power to vote and to dispose of 728,170 shares of Common Stock, representing 10.0% of the outstanding Common Stock. StoneGate Partners, LLC, by virtue of being a joint controller of Kairos GP with Aim High Enterprises, Inc., may be deemed to have shared power to vote and to dispose of 728,170 shares of Common Stock, representing 10.0% of the outstanding Common Stock. (c) The following is a description of all transaction in shares of Common Stock of the Issuer by the reporting person identified in Item 2 of this Schedule 13D effected from July 16, 2001 to July 30, 2001: None. (d) Not applicable (e) Not applicable ITEM 6. CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT TO SECURITIES OF THE ISSUER : Not applicable. ITEM 7. MATERIAL TO BE FILED AS EXHIBITS. Exhibit 99.1--Notice to Issuer proposing the nomination of four individuals for election to Issuer's Board of Directors at the next annual meeting of stockholders of the Issuer. Exhibit 99.2 Letter to Issuer informing the Issuer that Kairos intends to deliver a proxy statement and form of proxy to holders of at least the percentage of holders of Common Stock required under Georgia law to elect some or all of Kairos' nominees to the Issuer's Board of Directors at the next annual meeting of stockholders of the Issuer and requesting a current list of all record and beneficial holders of Common Stock (attachment to letter intentionally omitted). CUSIP No. 452526106 13D/A PAGE 8 OF 8 SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. August 14, 2001 --------------------------------- (Date) /s/ James F. Rice --------------------------------- (Signature) James F. Rice EX-99.1 3 a1026636.txt NOTICE Exhibit 99.1 VIA FEDERAL EXPRESS August 9, 2001 Mr. Steven C. Ramsey Secretary Immucor Inc. 3130 Gateway Drive Norcross, GA 30091-5625 Dear Mr. Ramsey, As you know, Kairos Partners, L.P. is currently a 10% holder of Immucor stock. As such, Kairos is entitled to vote at Immucor's Annual Meeting of shareholders at which directors will be elected. The following list of nominees is hereby submitted by Kairos to stand for election at Immucor's 2001 Annual Meeting or at the next shareholder meeting at which Directors of Immucor are elected. They are: 1. John F. McGuire, III 2. Ronald O. Gilcher, M.D., F.A.C.P. 3. Pierre G. Cassigneul 4. Peter R. White The information required with respect to each of the nominees is detailed in the attached Exhibits 1 through 4. By its signature below, Kairos Partners L.P. hereby certifies to Immucor that each of the nominees listed above has consented to be nominated for election to the Board of Directors of Immucor and that it believes that each nominee will stand for election and will serve as a Director, if elected. Sincerely, John F. White Kairos Partners, L.P. JFW/srh cc: E. Gallup/D. Lanson / D. Smith /R. Eatz / B. Papesh / J. Rosen / G. De Chirico / D. McKeithan EXHIBIT 1 Name: JOHN F. MCGUIRE, III Age: 54 years Business Address: Whatman Bioscience 200 Wells Avenue Newton, MA 02459 Residence Address: 178 West Bare Hill Road Harvard, MA 01451 Occupation: John F. McGuire, III, age 54, became President and Managing Director of Whatman Bioscience in June 2001. Prior to that Mr. McGuire served as Chief Executive Officer, President and a Director of HemaSure Inc. since April 1997. From 1988 to 1997, Mr. McGuire was employed by Johnson & Johnson, Inc., most recently as Vice President and General Manager of the Ortho Diagnostic Systems Blood Bank Business Unit since January 1996. From March 1995 to January 1996, Mr. McGuire held the position of Vice President, Sales & Marketing, North America for J&J. From August 1990 to March 1995, Mr. McGuire served as Managing Director of Ortho Diagnostic Systems, U.K. and Belgium for J&J. From September 1988 to August 1990, Mr. McGuire held the position of Marketing Director for the AIDS and Hepatitis Business Unit of J&J. From 1977 to 1988, Mr. McGuire held various management positions at E.I. DuPont De Nemours & Company, the last of which was National Sales Manager, AIDS & Hepatitis Business. Mr. McGuire is a member of the Board of Trustees of the National Blood Foundation Trust Fund. Affiliations: As a limited partner of Kairos Partners LP, Mr. McGuire may be deemed to be the beneficial owner of the shares of Immucor stock owned by Kairos Partners LP. However, Mr. McGuire disclaims beneficial ownership of such shares. Except as provided in the prior sentence, Mr. McGuire does not have any affiliation with, or material interest in Immucor or any transaction involving Immucor. In addition, Mr. McGuire does not have any affiliation with, or material interest in, any person or entity having an interest materially adverse to Immucor. EXHIBIT 2 Name: RONALD O. GILCHER, M.D., F.A.C.P. Age: 63 years Business Address: Sylvan N. Goldman Center Oklahoma Blood Institute 1001 N. Lincoln Boulevard Oklahoma City, OK 73104 Residence Address: 4021 Woodcutter Drive Oklahoma City, OK 73105 Occupation: Ronald O. Gilcher, M.D., F.A.C.P., age 63, has served as Chief Executive Officer, President and Medical Director of the Sylvan N. Goldman Center, Oklahoma Blood Institute ("OBI") since 1979. OBI is a nationally recognized independent blood center. From 1971 to 1979, Dr. Gilcher served at the Central Blood Bank of Pittsburgh, as Assistant Medical Director and Medical Director from 1974. During that time, Dr. Gilcher was also an Assistant Professor of Medicine and an Associate Professor of Clinical Medicine at the University of Pittsburgh, School of Medicine. Dr. Gilcher is Board Certified in Internal Medicine and Hematology and is a Fellow of the American College of Physicians. In 1997, Dr. Gilcher was appointed by the U.S. Department of Health and Human Services to serve on the Advisory Committee on Blood Safety and Availability. Affiliations: As a limited partner of Kairos Partners LP, Dr. Gilcher may be deemed to be the beneficial owner of the shares of Immucor stock owned by Kairos Partners LP. However, Dr. Gilcher disclaims beneficial ownership of such shares. Except as provided in the prior sentence, Dr. Gilcher does not have any affiliation with, or material interest in Immucor or any transaction involving Immucor. In addition, Dr. Gilcher does not have any affiliation with, or material interest in, any person or entity having an interest materially adverse to Immucor. EXHIBIT 3 Name: PIERRE G. CASSIGNEUL Age: 48 years Business Address: Bayer Corporation Diagnostics Division 511 Benedict Avenue Tarrytown, NY 10591-5097 Residence Address: 8 Haven Hill Rise Flemington, NJ 08822 Occupation: Mr. Cassigneul, age 48, has served as Senior Vice President, Group Business Operations, Planning and Communications of the Diagnostics Division of Bayer Corporation since June 2000. From February 1997 through June 2000, Mr. Cassigneul was Senior Vice President and General Manager of the Diabetes Self-Testing Segment of Bayer. Prior to that, Mr. Cassigneul was Vice President and General Manager of the AIDS and Hepatitis Business Unit of Ortho Diagnostic Systems (Johnson & Johnson, Inc.) from June 1991 through January 1997. From September 1982 through May 1991 Mr. Cassigneul held several General Management and Marketing positions with Abbott Laboratories Diagnostic Division both in the USA and in Europe. In 1985, he launched the first HIV test for screening the European blood supply while he was responsible for the Hepatitis product line and the blood screening business in Europe. Affiliations: Mr. Cassigneul does not have any affiliation with, or material interest in Immucor or any transaction involving Immucor. In addition, Mr. Cassigneul does not have any affiliation with, or material interest in, any person or entity having an interest materially adverse to Immucor. EXHIBIT 4 Name: PETER R. WHITE Age: 46 years Business Address: 44 Lowell Road Wellesley, MA 02481 Residence Address: 44 Lowell Road Wellesley, MA 02481 Occupation: Peter R. White, age 46, is currently self-employed as a financial consultant. From 1981 to 2001, Mr. White worked for Fleet Securities, Inc., and its predecessor companies BancBoston Robertson Stephens and BankBoston. Since 1993, he served as a Managing Director in units that financed the acquisition of businesses by private equity firms. Services included the providing of senior bank debt, private mezzanine debt, public high yield debt, private equity, and merger and acquisition advisory products. During this period, Mr. White was directly involved in analyzing, conducting comprehensive due diligence, underwriting, and distributing over $1 billion in new debt financings to highly leveraged companies across a broad range of industry sectors. Mr. White received an A.B. degree, cum laude, from Dartmouth College, and an M.B.A. in Finance from the Wharton School. Affiliations: Mr. White does not have any affiliation with, or material interest in Immucor or any transaction involving Immucor. In addition, Mr. White does not have any affiliation with, or material interest in, any person or entity having an interest materially adverse to Immucor. EX-99.2 4 a1026872.txt LETTER Exhibit 99.2 August 10, 2001 BY FEDERAL EXPRESS Mr. Steven C. Ramsey Secretary Immucor Inc. 3130 Gateway Drive Norcross, GA 30091-5625 Dear Mr. Ramsey, As you know, Kairos Partners, L.P. is currently a 10% holder of Immucor stock, as evidenced by the attached Schedule 13D Amendment No. 5 which was filed with the SEC on August 3, 2001. As such, Kairos is entitled to vote at the next meeting of Immucor's stockholders, which we expect will be the 2001 Annual Meeting, in advance of which, we expect Immucor will make a proxy solicitation with respect to, among other things, the election of nominees to Immucor's Board of Directors. In addition, on August 9, 2001, Kairos delivered notice to Immucor, in accordance with Immucor's By-laws, proposing four nominees to stand for election to Immucor's Board of Directors at the 2001 Annual Meeting (or the next meeting of Immucor's stockholders, if not the 2001 Annual Meeting). Pursuant to Rule 14a-4(c)(2) of the rules and regulations of the Securities and Exchange Commission promulgated under the Securities Exchange Act of 1934, as amended, by this letter, Kairos hereby notifies Immucor that Kairos intends to deliver a proxy statement and form of proxy to holders of at least the percentage of holders of Immucor stock required under Georgia law to elect some or all of Kairos' nominees to the Immucor Board of Directors at the 2001 Annual Meeting (or the next stockholders meeting, if not the annual meeting). In addition, pursuant to Rule 14a-7 under the Securities Exchange Act of 1934, Kairos hereby requests that Immucor provide Kairos with a current list of all record and beneficial holders of Immucor stock in accordance with the requirements set forth in Rule 14a-7. By its signature below, Kairos hereby declares, affirms and attests that: 1. The proposal that will be the subject of Kairos' solicitation in connection with the 2001 Annual Meeting (or the next stockholders meeting, if not the annual meeting), is Kairos' proposal to elect some or all of its nominees to the Immucor Board of Directors, for which we expect Immucor will also make a proxy solicitation; 2. Kairos will not use the list information for any other purpose other than to solicit Immucor stockholders in connection with the 2001 Annual Meeting (or the next stockholders meeting, if not the annual meeting); and 3. Kairos will not disclose the list information to any person other than a beneficial owner for whom this request is made and an employee or agent of Kairos to the extent necessary to effectuate its solicitation. We look forward to receiving the current Immucor stockholder list by August 17, 2001. Sincerely, John F. White Kairos Partners, L.P. JFW/srh Enc. cc: E. Gallup/D. Lanson / D. Smith /R. Eatz / B. Papesh / J. Rosen / G. De Chirico / D. McKeithan -----END PRIVACY-ENHANCED MESSAGE-----